Lv1
70 积分 2022-09-14 加入
Development and validation of an in vitro permeation test method for rectal mesalamine suppositories
11小时前
求助中
Statistical approaches to classify investigational product using hERG safety assay
11小时前
已完结
A survey of parallelism testing methods for bioassays
11小时前
已完结
An exploratory application of modern statistical methodology and machine learning techniques in assessment of crystallinity monitoring and control strategy development for high-risk drug manufacturing
11小时前
待确认
Consultation report - gonococcal immunoassays and standards for vaccine development
11小时前
求助中
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09
3个月前
已完结
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05
3个月前
已关闭
7O Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07
3个月前
已关闭
皖公网安备34019202002308
